Barnik Invest Acquires Idogen’s Technology Platform to Advance Immunotherapy

Stockholm, Sweden – Barnik Invest Group today announced the acquisition of Idogen AB’s technology platform. This strategic move positions Barnik Invest to lead the development of innovative therapies based on antigen-specific dendritic cell-mediated tolerance. The acquired technology platform holds immense potential to treat autoimmune diseases by modulating the immune system to target specific antigens. By […]